ATNM Actinium Pharmaceuticals Inc. (Delaware)

0.21
+0.01  (+6%)
Previous Close 0.2
Open 0.21
Price To Book 2.15
Market Cap 35,328,400
Shares 164,701,167
Volume 783,840
Short Ratio 1.42
Av. Daily Volume 1,762,125
Stock charts supplied by TradingView

NewsSee all news

  1. Actinium Pharmaceuticals to Present at the 25th Annual BIO-Europe® 2019 International Partnering Conference

    NEW YORK, Nov. 7, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium") announced today that it will attend the 25th Annual BIO-Europe® International Partnering Conference being held

  2. Actinium Announces Interim Results from Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML Accepted for Presentation at ASH 2019

    NEW YORK, Nov. 6, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium") today announced that interim results from a Phase 1 trial studying Actimab-A in combination with CLAG-M have been

  3. Actinium Pharmaceuticals to Present New Clinical Findings from SIERRA Trial Supporting the Iomab-ACT Program for Targeted Lymphodepletion for CAR-T and Adoptive Cell Therapies at ASH 2019

    NEW YORK, Nov. 6, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium") today announced that new findings from its pivotal Phase 3 SIERRA trial for Iomab-B (Iodine-131 apamistamab) that

  4. Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment

    NEW YORK, Oct. 28, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium") today announced key interim findings from the pivotal Phase 3 SIERRA trial of Iomab-B, including

  5. Actinium Announces Participation at the 2019 Cell & Gene Meeting on the Mesa

    NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium") today announced that it will be attending the 2019 Cell & Gene Meeting on the Mesa being held October 2nd –

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 trial planned, to be followed by pivotal trial.
Actimab-MDS
Myelodysplastic syndrome (MDS)
Phase 2 data presented at TAT April 2, 2019.
Actimab-A
Acute Myeloid Leukemia (AML)
Phase 3 data due at ASH December 7, 2019 at 5:30pm ET.
Iomab-B
Acute myeloid leukemia (AML)
Phase 1 ongoing.
Actimab-M
Refractory multiple myeloma
Phase 1 data due at ASH December 8, 2019 at 6pm EST.
Actimab-A in combination with CLAG-M
Relapsed or refractory acute myeloid leukemia (AML)
Phase 1/2 trial initiation announced February 5, 2019.
Actimab-A and Venetoclax
Relapsed or refractory acute myeloid leukemia (AML)

Latest News

  1. Actinium Pharmaceuticals to Present at the 25th Annual BIO-Europe® 2019 International Partnering Conference

    NEW YORK, Nov. 7, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium") announced today that it will attend the 25th Annual BIO-Europe® International Partnering Conference being held

  2. Actinium Announces Interim Results from Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML Accepted for Presentation at ASH 2019

    NEW YORK, Nov. 6, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium") today announced that interim results from a Phase 1 trial studying Actimab-A in combination with CLAG-M have been

  3. Actinium Pharmaceuticals to Present New Clinical Findings from SIERRA Trial Supporting the Iomab-ACT Program for Targeted Lymphodepletion for CAR-T and Adoptive Cell Therapies at ASH 2019

    NEW YORK, Nov. 6, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium") today announced that new findings from its pivotal Phase 3 SIERRA trial for Iomab-B (Iodine-131 apamistamab) that

  4. Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment

    NEW YORK, Oct. 28, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium") today announced key interim findings from the pivotal Phase 3 SIERRA trial of Iomab-B, including

  5. Actinium Announces Participation at the 2019 Cell & Gene Meeting on the Mesa

    NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium") today announced that it will be attending the 2019 Cell & Gene Meeting on the Mesa being held October 2nd –

  6. Actinium Announces Iomab-B Poster Selected for Honorable Distinction Award at the 2019 Society of Hematologic Oncology Annual Meeting from Nearly Four Hundred Abstracts

    NEW YORK, Sept. 23, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium") today announced that a poster highlighting Iomab-B, its pivotal Phase 3 targeted conditioning candidate, was

  7. Actinium Pharmaceuticals to Present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering & Investment

    NEW YORK, Sept. 16, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium") today announced that it will present at the Sachs 19th Annual Biotech in Europe Forum for Global Partnering &

  8. Actinium Pharmaceuticals to Present at the Rodman & Renshaw 21st Annual Global Investment Conference

    NEW YORK, Sept. 5, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium"), today announced that it will present at the Rodman & Renshaw 21st Annual Global Investment Conference. The